Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is nonsmall cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing. The report forecasts the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. Covered in this report The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key regions - Americas - APAC - Europe Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon
- Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Market drivers - Promising drug pipeline - For a full, detailed list, view the full report Key Market challenges - High cost of therapy - For a full, detailed list, view the full report Key Market trends - Personalized medicine - For a full, detailed list, view the full report Key questions answered in this report - What will the market size be in 2019 and what will the growth rate be? - What are the key Market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Contents: PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Product profiles PART 05: Introduction Key market highlights PART 06: Disease overview Understanding the disease Risk factors Signs and symptoms Diagnosis Staging Treatment Epidemiology PART 07: Pipeline portfolio Information on pipeline candidates
PART 08: Market landscape Market overview Market size and forecast Five forces analysis PART 09: Market segmentation by molecule type Biologics Small molecules PART 10: Market segmentation by route of administration Oral Parenteral PART 11: Geographical segmentation PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape Competitive scenario Market analysis 2014 Other prominent vendors PART 18: Key vendor analysis AstraZeneca Celgene Eli Lilly F. Hoffmann-La Roche Pfizer PART 19: Appendix List of abbreviations PART 20: About the Author List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of non-small cell lung cancer Exhibit 03: Gene mutations in non-small cell lung cancer Exhibit 04: Risk factors for non-small cell lung cancer Exhibit 05: Signs and symptoms of non-small cell lung cancer Exhibit 06: Tests for diagnosis of non-small cell lung cancer Exhibit 07: Staging of non-small cell lung cancer Exhibit 08: Management of non-small cell lung cancer Exhibit 09: Types of radiation therapy for non-small cell lung cancer Exhibit 10: Photodynamic therapy uses light to actuate a drug in the body, which kills abnormal cells.nonsmall cell lung cancer treatment algorithm Exhibit 11: Phase III pipeline molecules for non-small cell lung cancer Exhibit 12: Global non-small cell lung cancer therapeutics market 2014-2019 ($ billions) Exhibit 13: Five forces analysis Exhibit 14: Global non-small cell lung cancer therapeutics market segmentation by molecule type Exhibit 15: Global non-small cell lung cancer therapeutics market segmentation by route of administration Exhibit 16: Global non-small cell lung cancer market by geographical segmentation 2014 Exhibit 17: Impact of drivers Exhibit 18: Impact of drivers and challenges Exhibit 19: F. Hoffmann-La Roche: Global YoY growth and revenue of Avastin 2011-2014 ($ millions)
Exhibit 20: F. Hoffmann-La Roche: Key takeaways Exhibit 21: Alimta: Global YoY growth and revenue 2011-2014 ($ millions) Exhibit 22: Gemzar: Global YoY growth and revenue 2008-2011 ($ millions) Exhibit 23: Eli Lilly: Key takeaways Exhibit 24: Abraxane: Global YoY growth and revenue 2011-2014 ($ millions) Exhibit 25: Celgene: Key takeaways Exhibit 26: Iressa: Global YoY growth and revenue 2011-2014 ($ millions) Exhibit 27: Iressa: YoY growth and revenue in Western Europe 2011-2014 ($ millions) Exhibit 28: Iressa: YoY growth and revenue in established ROW 2011-2014 ($ millions) Exhibit 29: Iressa: YoY growth and revenue in emerging markets 2011-2014 ($ millions) Exhibit 30: AstraZeneca: Key takeaways Exhibit 31: Xalkori: Global YoY growth and revenue 2012-2014 ($ millions) Exhibit 32: Pfizer: Key takeaways Exhibit 33: AstraZeneca: Business segmentation by revenue 2014 Exhibit 34: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 35: AstraZeneca: Geographical segmentation by revenue 2014 Exhibit 36: Celgene: Product segmentation by revenue 2014 Exhibit 37: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions) Exhibit 38: Celgene: Geographical segmentation by revenue 2014 Exhibit 39: Eli Lilly: Business segmentation by revenue 2014 Exhibit 40: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 41: Eli Lilly: Geographical segmentation by revenue 2014 Exhibit 42: F. Hoffmann-La Roche: Business segmentation by revenue 2014 Exhibit 43: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 44: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014 Exhibit 45: Pfizer: Business segmentation by revenue 2014 Exhibit 46: Pfizer: Geographical segmentation by revenue 2014 Ordering: Order Online - http://www.researchandmarkets.com/reports/3453273/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: http://www.researchandmarkets.com/reports/3453273/ SC Single User: 1-5 Users: Site License: Enterprisewide: Quantity USD 2500 USD 3000 USD 4000 USD 10000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 1 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World